Speakers
- Chair — Howard Wachtler, CEO, Actinium Pharmaceuticals
- Philip G. Green, Ph.D., Director Alternative Delivery Systems, BD-Medical Pharmaceutical Systems
- Dr. Ron Forster, Director Drug Product & Device Development, Amgen
- Yael Weiss, MD, Ph.D, Director Licensing and External Research, Merck & Co.
- Allen Downs, Sr Executive Director Licensing & Business Development, Purdue Pharma L.P.
- Mark Bunger, Research Director, Lux Research
- Jonathan M. Rigby, Co Founder and Vice President Business Development, Zogenix Inc.
- Walter Gacek, Director of Business Development, Accellent
- Tatyana Naranda, Director Business Development, Alexza Pharmaceuticals
- Dragan Cicic, MD, Medical Director, Actinium Pharmaceuticals
- Dr. Claire Evans, Director Protein Therapeutics, Ichor Medical Systems
- Janet Linn, JD, Pharmaceutical Intellectual Property Expert
- Shawn Chen, Ph.D, Asst Professor, Stanford University School of Medicine
- Dr. Peter Scholes, VP Pharmaceutical Sciences, Pharmaceutical Profiles Ltd.
- Matthew Kim, JD, Founder, Vice President Licensing and Business Development, Aerovectrx
- Dr. Verne Cowles, Sr. Director of Preclinical Studies, Depomed
- Andrew Forman, Financial Analyst (*#1 Pharmaceutical Analyst Wall Street Journal Survey, Forbes May 2006”*)
- Judith Kornfeld, Vice President of Business Development, TransPharma Medical
- Charles Hardy, Ph.D., MBA, President, Biovaluation and Analysis